Takeda holds full share of the Elaprase market in 2024

The Elaprase market is fully concentrated around Takeda Pharmaceutical Company, which held 100% global sales share in 2024, according to The Business Research Company. The report points to biologics manufacturing barriers, orphan drug exclusivity, and new blood-brain barrier delivery technology as the main forces shaping future competition in rare disease treatment.

Why it matters: - Elaprase sits in a rare disease market where one company controls all reported global sales, leaving little room for conventional competition. - The market’s structure shows how orphan drug rules, biologic manufacturing complexity, and specialized care networks can lock in long-term dominance. - New delivery technologies could reshape Hunter syndrome treatment if they move from clinical testing to broader use.

What happened: - The Business Research Company said Takeda Pharmaceutical Company led global Elaprase sales in 2024 with a 100% market share. - The report identified Takeda as the only major company operating in the Elaprase market. - The report was published July 9, 2026. - Takeda’s rare disease portfolio includes enzyme replacement therapy capabilities tied to Elaprase.

The details: - The market is described as highly concentrated, with the top player accounting for 100% of total market revenue in 2024. - The report links that concentration to orphan drug exclusivity, complex biologic manufacturing requirements, specialized treatment protocols, and the need for rare disease expertise. - Takeda’s position is supported by an established enzyme replacement therapy portfolio, global rare disease treatment presence, specialized commercialization capabilities, and long-standing focus on lysosomal storage disorder management. - Major raw material suppliers listed in the report include Merck KGaA, Thermo Fisher Scientific, Sartorius, Danaher, Lonza, FUJIFILM Irvine Scientific, Avantor, Repligen, AGC Biologics, Wacker Chemie, Roquette Frères, Evonik, Ashland, West Pharmaceutical Services, Corning, Bio-Rad Laboratories, Solenis, Mitsubishi Gas Chemical, 3M, and Charles River Laboratories. - Major wholesalers and distributors listed in the report include Cencora, Cardinal Health, Morris & Dickson, FFF Enterprises, Anda, CuraScript SD, ASD Healthcare, Specialty Care Distribution, Owens & Minor, Independent Pharmaceutical Cooperative, BioCareSD, Pharmaceutical Associates, Medline, McKesson Specialty Care Distribution, McKesson Plasma and Biologics, Cardinal Health Specialty Pharmaceutical Distribution, Accredo Health Group, CVS Specialty, and Optum Specialty Pharmacy. - Major end users listed in the report include Boston Children’s Hospital, Cincinnati Children’s Hospital Medical Center, Children’s Hospital of Philadelphia, Texas Children’s Hospital, Great Ormond Street Hospital, Royal Children’s Hospital Melbourne, University College London Hospitals NHS Foundation Trust, Charité – Universitätsmedizin Berlin, Hospital Sant Joan de Déu Barcelona, Apollo Hospitals, Fortis Healthcare, Max Healthcare Institute, National University Hospital Singapore, KK Women’s and Children’s Hospital, SickKids Toronto, NewYork-Presbyterian Hospital, Johns Hopkins Hospital, and Stanford Health Care. - The report also highlighted updated 2026 market-report features including market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, market hotspot infographics, and future trend analysis.

Between the lines: - The competitive picture suggests Elaprase is less a conventional drug market and more a highly protected rare disease franchise. - Blood-brain barrier-penetrating enzyme replacement technology is the clearest source of future disruption because it targets neurological symptoms that standard enzyme replacement therapy has struggled to address. - Denali Therapeutics reported positive clinical data in February 2025 for DNL310, also called tividenofusp alfa, an investigational Hunter syndrome therapy designed to deliver iduronate-2-sulfatase across the blood-brain barrier. - The report says the program’s central nervous system delivery mechanism, biomarker reduction outcomes, and potential for long-term neurological improvement could push the field beyond conventional enzyme replacement approaches.

What’s next: - The report expects demand for rare disease diagnosis expansion, treatment accessibility improvements, specialized therapeutic support, and advanced biologic therapies to reinforce market development. - The report says portfolio development, healthcare network expansion, and patient-focused initiatives could strengthen Takeda’s position further. - Companies are also emphasizing advanced enzyme replacement therapies, blood-brain barrier-penetrating technologies, strategic clinical development, increased rare disease research, and patient support programs. - Request a free sample of the report or view the full market report.

The bottom line: - Takeda owns the current Elaprase market, but next-generation delivery technology could define the first real competitive shift in Hunter syndrome therapy.